ESMO22 Preview 1 – what to watch out for in breast cancer
This year seems to be going all to quickly as we have arrived in time for the annual ESMO Preview series.
This year we have a lot of topics to cover from a review of various solid tumour types, novel targets and developmental therapeutics, hematologic malignancies, as well as various IO and cell therapy related readouts.
As always, the goal of our previews is to not only provide some context for what to expect, but also to highlight potential success and failures since not all of the trials have been headlined by the companies concerned.
It’s all to easy to forget agents in the same class of therapeutics can produce quite different outcomes despite similarly looking trial designs, as we will find out…
To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers